Document Detail

Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.
MedLine Citation:
PMID:  11401194     Owner:  NLM     Status:  MEDLINE    
The pharmacodynamic properties of low-molecular-weight heparins differ. Data from randomized clinical trials show that despite these differences, the agents have similar efficacy and safety profiles in preventing and treating new and recurrent venous thromboembolism in patients who underwent general surgery or total hip or knee replacement. Dalteparin, enoxaparin, or tinzaparin, when administered at the dosages used in the reviewed clinical trials, are essentially indistinguishable.
L M Lopez
Related Documents :
9549534 - Dalteparin for deep venous thrombosis: a hospital-in-the-home program.
20431444 - Nurse-driven intravenous heparin protocol: quality improvement initiative.
6993494 - Can the results of treatment of deep venous thrombosis be improved by combining surgica...
11210954 - Graduated compression stockings: knee length or thigh length.
17000454 - Surgical outcome of aortopulmonary window repair in early infancy.
7097964 - Replicable abstinence rates in an alcoholism treatment program.
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Pharmacotherapy     Volume:  21     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-06-12     Completed Date:  2001-12-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  56S-61S; discussion 71S-72S     Citation Subset:  IM    
College of Pharmacy, University of Florida, Gainesville 32610-0486, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Dalteparin / administration & dosage,  adverse effects,  therapeutic use*
Enoxaparin / administration & dosage,  adverse effects,  therapeutic use*
Heparin, Low-Molecular-Weight / administration & dosage,  adverse effects,  therapeutic use*
Pulmonary Embolism / drug therapy,  prevention & control
Venous Thrombosis / drug therapy*,  prevention & control*
Reg. No./Substance:
0/Dalteparin; 0/Enoxaparin; 0/Heparin, Low-Molecular-Weight; 0/tinzaparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New developments in the prevention and treatment of venous thromboembolism.
Next Document:  Differentiation of the low-molecular-weight heparins.